NCT07507942

Brief Summary

The issue of rare diseases has become a public health priority. In France, a national plan for rare diseases was published in 2004. It leads to the creation and certification of numerous Rare Disease Reference Centers by the French National Authority for Health (Haute Autorité de Santé). Our Fibrous Dysplasia Reference Center has been certified since 2006. However, evaluating the mechanical strength and fracture risk of fibrous dysplasia lesions remains a major unresolved challenge for clinicians. Improving the assessment of fracture risk therefore represents a key clinical objective.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
7mo left

Started Mar 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Mar 2025Mar 2027

Study Start

First participant enrolled

March 10, 2025

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

February 12, 2026

Completed
26 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2026

Completed
23 days until next milestone

First Posted

Study publicly available on registry

April 2, 2026

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2027

Expected
Last Updated

April 2, 2026

Status Verified

February 1, 2026

Enrollment Period

1 year

First QC Date

February 12, 2026

Last Update Submit

March 30, 2026

Conditions

Keywords

Fibrous dysplasiaMcCune AlbrightMEKANOS toolMAS-DFbone diseasefracture risk in rare bone disease

Outcome Measures

Primary Outcomes (1)

  • Tool X

    Obtaining an image suitable for processing with tool X in order to compute failure strength through numerical simulation (i.e., adequate bone segmentation and a correctly implemented numerical model with appropriate boundary conditions).

    CT scans of Patients with femoral fibrous dysplasia lesions performed from January 2002 until 9 March 2025.

Study Arms (1)

CT scans of Patients with femoral fibrous dysplasia lesions identified in the Easily HYBRID DF datab

Application of MEKANOS tool to CT scans.

Other: Application of MEKANOS tool to CT scans

Interventions

MEKANOS tool is an algorithm that automatically segments femurs from clinical CT scans, generates a numerical model, and performs a numerical simulation of single leg stance loading on these femurs. The tool is developed within INSERM unit 1033 and is currently available only in the laboratory. Input data consist of CT imaging (DICOM format) and retrospective clinical data. The output is the failure load expressed in Newtons.Interpretation of the results involves determining fracture risk based on the failure load (pathological bone versus healthy bone), and then integrating patient size and weight. CT Scans are issued from the HCL PACS, and clinical data issued from Easily Hybrid DF database.

CT scans of Patients with femoral fibrous dysplasia lesions identified in the Easily HYBRID DF datab

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Clinical data issued from Easily HYBRID DF Database, and CT images of long bones acquired during routine clinical care and retrieved from the HCL imaging..

You may qualify if:

  • Adults with Fibrous Dysplasia (FD) of the bone or McCune-Albright Syndrome (MAS);
  • who have received care at the center through outpatient consultation, multidisciplinary evaluation, or hospitalization;
  • whose diagnosis was confirmed by an expert physician from the reference center based on a combination of clinical, biochemical, and radiological criteria, in accordance with the recommendations of the international FD/MAS consortium (Javaid MK et al., Orphanet J Rare Dis. 2019);
  • for whom a histological confirmation was obtained in cases of diagnostic uncertainty;
  • no objection to data collection

You may not qualify if:

  • \- CT scan with implanted material on the femur,
  • Individuals under legal protection measures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Edouard Herriot Hospital - rheumatology

Lyon, Lyon, 69003, France

Location

MeSH Terms

Conditions

Fibrous Dysplasia of BoneFibrous Dysplasia, PolyostoticBone Diseases

Condition Hierarchy (Ancestors)

OsteochondrodysplasiasBone Diseases, DevelopmentalMusculoskeletal Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 12, 2026

First Posted

April 2, 2026

Study Start

March 10, 2025

Primary Completion

March 10, 2026

Study Completion (Estimated)

March 10, 2027

Last Updated

April 2, 2026

Record last verified: 2026-02

Locations